Developing and validating a Global Trigger Tool for assessing frequency, level of harm, and preventability of adverse

Amit Gutkind1, Amos Toren2,3, Raz Somech3,4

  • 1Quality and Safety Unit, Sheba Medical Center, Tel Hashomer, Ramat Gan 5262000, Israel.

Insights

The adapted Pediatric Trigger Tool (PTT) effectively identifies adverse drug events (ADEs) in Israeli pediatric wards, finding significantly more ADEs than voluntary reporting. This tool enhances patient safety by detecting preventable medication errors.

Area of Science:

  • Pediatric pharmacology
  • Patient safety research
  • Health informatics

Background:

  • Medications are a significant source of patient harm in hospitals, contributing to approximately 20% of all medical injuries.
  • Adverse drug events (ADEs) during pediatric hospitalizations occur at a high rate, ranging from 11 to 40 per 100 hospitalizations, with a 1% mortality rate.

Purpose of the Study:

  • To adapt and validate the Pediatric Trigger Tool (PTT) for use in Israeli pediatric wards.
  • To assess the rate of ADEs in pediatric hospitalizations using the adapted PTT.
  • To compare the PTT's ADE detection capabilities with voluntarily reported events.

Main Methods:

  • A retrospective comparative study utilizing medical records from 700 pediatric hospitalizations (2015-2017).
  • Validation of the adapted PTT on internal and surgical pediatric wards at an academic medical center.
  • Analysis of ADEs, including timing, preventability, and severity, and comparison with staff-reported data.

Main Results:

  • The adapted PTT identified 108 ADEs in 78 hospitalizations, with an ADE rate of 15.4 per 100 hospitalizations.
  • The tool detected 10.8 times more ADEs than voluntary reporting, with 18.5% deemed preventable.
  • Painkillers were the most frequent cause of ADEs, leading to adverse clinical effects such as constipation and hypokalemia.

Conclusions:

  • The adapted Pediatric Trigger Tool is a valuable instrument for detecting adverse drug events in pediatric inpatient settings.
  • Implementation of the PTT can significantly improve the identification of medication-related harm in children.
  • The findings underscore the importance of robust systems for monitoring and preventing ADEs in pediatric care.
Abstract

Related Concept Videos

Pharmacovigilance01:19

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
769
Healthcare Associated Infections II: Preventive Measures01:22

Healthcare Associated Infections II: Preventive Measures

Essential infection prevention measures are based on the knowledge of the infection chain, the modes of transmission in healthcare settings, and the use of the best practices in all healthcare settings. Compulsory public reporting of healthcare-associated infection rates is needed to allow individuals and the community to make informed choices regarding selecting a healthcare facility.
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...
2.4K
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.8K
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K